RYBODYN AWARDED $1.3M DOW GRANT TO ADVANCE NOVEL ANTIBODY THERAPIES FOR LUNG CANCER

Competitive CDMRP award funds preclinical programs against two cryptic cell-surface targets discovered directly in patient tumors using the company's AI-powered RyboCypher™ platform and CypherAtlas™ knowledgebase SAN DIEGO, July 9, 2026 /PRNewswire/ -- RyboDyn, Inc., a biotechnology...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.